Mitochondria’s First FDA-Approved Drug: SS-31 Explained

SS-31 (Elamipretide) just became the first FDA-approved mitochondrial-targeted therapy—for Barth syndrome under accelerated approval. Here’s how it works (cardiolipin binding), what the human data shows, and how it compares to MOTS-c and BAM15. Educational only.

Follow me on all socials:
@Spideytwocents (Instagram, YouTube, X)
@fossil.fitness (TikTok)

For your research journey:
👉 herolabspeptides.com

Verse of the Day:

“But those who hope in the LORD will renew their strength…” — Isaiah 40:31

Sources / Further Reading:

FDA Press Release (Accelerated Approval, Sept 19, 2025)

Mechanism: Cardiolipin stabilization & mitochondrial structure

Human data: TAZPOWER Trial results

MOTS-c: Mitochondrial-encoded peptide research

BAM15: Mitochondrial uncoupler fat-loss studies

Disclaimer:
This video is for educational purposes only and not medical advice. Do not use this information to diagnose or treat any condition.